Locations:
Search IconSearch
April 10, 2018/Neurosciences

PACNS or RCVS? Differences in Imaging and Test Results

Why precise diagnosis matters

By Rula Hajj-Ali, MD, and Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

An extensive workup is required to rule out primary angiitis of the central nervous system (PACNS), a devastating disease in which exclusive inflammation and destruction of vessels in the CNS cause progressive, debilitating neurological deficits. Prognosis improves greatly with proper treatment, but with nonspecific tests and many confounding mimics, diagnosis can be tricky.

One of PACNS’s closest mimics is reversible cerebral vasoconstriction syndrome (RCVS). Distinguishing between RCVS and PACNS is critical because the treatment protocol is so vastly different. Misdiagnosing PACNS as RCVS can deprive a patient of medications that prolong survival and improve outcomes. We offer a brief overview of differences in the results of diagnostic tests below. See this post for differences in clinical presentation. A future post will focus on management.

Diagnostic test results

Cerebrospinal fluid (CSF) analysis is essential in the differentiation between PACNS and RCVS and in excluding infections and malignancies. PACNS cases will show lymphocyte-predominant pleocytosis, elevated protein levels and normal glucose levels. In RCVS, normal CSF is the rule, unless the CSF is contaminated by subarachnoid or parenchymal hemorrhages.

Neuroimaging in PACNS cases is always abnormal. Ischemic infarctions are the most common lesions and are often multiple and bilateral. Nonspecific high-intensity lesions are also common in PACNS as visualized on T2-weighted magnetic resonance imaging (MRI) with a fluid-attenuated recovery sequence. RCVS is usually but not always abnormal on neuroimaging. Upon initial presentation, 20 percent of patients may have normal neuroimaging. Edema is a common finding, and computed tomography can show convexity subarachnoid hemorrhage or intracranial hemorrhage, both more common in RCVS.

Advertisement

Cerebrovascular imaging is always abnormal in RCVS and usually abnormal in PACNS. Stenosis and dilation visualized by direct or indirect angiography are not specific to either condition. Involvement of vascular beds in RCVS is usually bilateral and affecting multiple territories which may not be true in PACNS. Further, the cerebrovascular abnormalities in RCVS are dynamic and improve over time.

In the lab, both PACNS and RCVS will test normal for C-reactive protein, erythrocyte sedimentation rate, complete blood count and complete metabolic profile. Serologic tests for rheumatologic, autoinflammatory, autoimmune, malignant and infectious diseases are negative in PACNS and RCVS.

Advances in neuroimaging such as the use of 3-Tesla high resolution MRI specifically to assess the vessel wall hold promise in differentiating between both entities. The vessel walls in RCVS do not show enhancement while in PACNS enhancement occurs.

A note on the gold standard

Brain biopsy is the often-feared, underutilized gold standard in the diagnosis of PACNS. An open-wedge procedure is considered low risk, and an experienced neurosurgeon working as part of a multidisciplinary team can perform a biopsy with greater than 80 percent sensitivity and 90-100 percent specificity. Finding inflammation in the vessel wall is characteristic of PACNS, while brain biopsies are normal in RCVS.

Dr. Hajj-Ali is Associate Director of the Center for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology.

Advertisement

Advertisement

Related Articles

middle-aged woman with surgical mask looking out a window
Registry Studies Reassure on Impact of COVID-19 in People With MS

No effect on symptom severity or disability, and low prevalence of long COVID

network of nerves on the side of the face
January 14, 2025/Neurosciences/Brain Tumor
Preemptive Facial Nerve Rewiring in the Management of Facial Nerve Tumor: A Case Study

Novel approach begins reinnervation before tumor resection, preserving a young woman’s smile

Medical illustration of brain
January 6, 2025/Neurosciences/Research
Department of Defense Awards $3.4 Million to Advance a Tool for Assessing Return-to-Duty Readiness After Brain Injury

Cleveland Clinic researchers collaborate with Microsoft to create a product ready for the field

smartwatch being strapped to a woman's wrist
December 20, 2024/Neurosciences/Brain Tumor
Can Smartwatch Data Predict Progression and Detect Complications in Patients With Glioblastoma?

Researchers use AI tools to compare clinical events with continuous patient monitoring

Dr. Charles Bernick against a decorative backdrop
December 13, 2024/Neurosciences/Podcast
Considerations Around the Use of Anti-Amyloid Agents for Alzheimer’s Disease (Podcast)

Guidance on patient selection, safety surveillance, choosing among agents and more

macrophages and microglia in glioblastoma tumors
December 3, 2024/Neurosciences/Brain Tumor
Dual Targeting of Macrophages and Microglia Shows Promise in Preclinical Glioblastoma Models

Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression

portrait of dr. demitre serletis against decorative background
December 2, 2024/Neurosciences/Podcast
SEEG in Epilepsy Surgery Evaluation: Current and Future Roles (Podcast)

Insights on how stereoelectroencephalography is continuing to improve seizure localization

brain map showing planned electrode placement
November 25, 2024/Neurosciences/Epilepsy
What We’ve Learned From Our First 1,000 Cases of SEEG Evaluation

Progress in stereoelectroencephalography for epilepsy surgery evaluation since Cleveland Clinic performed the first U.S. case in 2009

Ad